 <h1>Skelid Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>tiludronate</i></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Professional</li>
<li>Interactions</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about tiludronate. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Skelid.</p><p><i>Applies to tiludronate: oral tablet</i></p><h3>General</h3><p>The most frequently occurring adverse reactions reported were: Diarrhea (9.3%), nausea (9.3%), and dyspepsia (5.3%).<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, flushing<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, skin disorder, pruritus, increased sweating<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hyperparathyroidism<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, nausea, dyspepsia, vomiting, flatulence, tooth disorder, abdominal pain, constipation, dry mouth gastritis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Vitamin D deficiency, anorexia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Bone, joint, and/or muscle pain, rarely severe and/or incapacitating have been reported.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Arthralgia, back pain, arthrosis, fracture pathological, skeletal pain</p><p><b>Postmarketing reports</b>: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, including this drug<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, paresthesia, vertigo, involuntary muscle contractions, somnolence, nervousness<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataract, conjunctivitis, glaucoma<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Pain, accidental injury, influenza like symptoms, chest pain, peripheral edema, infection, asthenia, syncope, fatigue<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia, anxiety<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Rhinitis, sinusitis, upper respiratory tract infection, coughing, pharyngitis, bronchitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Stevens-Johnson syndrome<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_4">4. "Product Information. Skelid (tilundronate)." Sanofi Winthrop Pharmaceuticals, New York, NY. </p><p id="ref_5">5. Roux C, Listrat V, Villette B, Lessana-Leibowitch M, Ethgen D, Pelissier C, Dougados M, Amor B "Long-lasting dermatological lesions after tiludronate therapy." Calcif Tissue Int 50 (1992): 378-80</p><p id="ref_6">6. Reginster JY, Lecart MP, Deroisy R, Ethgen D, Zegels B, Franchimont P "Paget's disease of bone treated with a five day course of oral tiludronate." Ann Rheum Dis 52 (1993): 54-7</p><p id="ref_7">7. Fraser WD, Stamp TC, Creek RA, Sawyer JP, Picot C "A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone." Postgrad Med J 73 (1997): 496-502</p><h2>More about Skelid (tiludronate)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Imprints, Shape &amp; Color Data</li>
<li>Drug Interactions</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (3)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Paget's Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>